Overview
Founded in 2009, the Infectious Diseases Department of Sir Run Run Shaw Hospital, has become a professional team integrating medical treatment, teaching and scientific research.
The Infectious Disease Department has a group of experienced clinical experts who are able to provide the most accurate and prompt treatment for a wide range of infectious diseases, including: fever of undetermined origin (FUO), severe bacterial infectious diseases, multi-drug resistant bacteria infections, fungal infections, tuberculosis, parasite infections, viral hepatitis, complicated liver diseases, and cirrhosis.
The Infectious Diseases Department also has a scientific research team whose members are sparing no effort to deepen their knowledge of pathogen characteristics and mechanisms of infectious diseases. We are working hard to integrate advances in laboratory research into clinical diagnosis and patient care. Some of our physicians are making great contributions in many areas of microbiology research and have been awarded many national grants. Our research interests include the molecular genetics of β-lactamases in Gram-negative bacilli, the resistance mechanism of tigecycline and colistin in Gram-negative bacilli, and epidemiology and pathogenesis of diseases caused by community-acquired Methicillin-Resistant Staphylococcus Aureus.
Members：
11 attendings
5 fellows
6 residents
1 medical assistant
Among them, 15 have doctor’s degree, 3 are Doctorial Supervisor and 3 are Master Supervisor.
Sub-specialties of the Members
Fever of undetermined origin
Viral hepatitis
Central nervous system infections
Extra-pulmonary tuberculosis
Academic Status
Training center for physicians and residents of Infectious Diseases
Innovative discipline of Zhejiang province (clinical microbiology)
Research center for diagnosis and treatment of multi-drug resistant bacterial infection
ESCMID collaborating center
Training center of bacterial and fungal infection in China
National health promotion project: fatty liver diagnosis and treatment center
Medical Care Service
1) Fever of unknown origin: The etiology can involve all systems of the whole body. Our department has treated a large number of cases, including various difficult and miscellaneous diseases, and has established a system and standardized process for the diagnosis and treatment of FUO.
2) Complicated and critical liver diseases: We have rich experience and conduct in-depth research in autoimmune liver diseases, metabolic liver diseases, hereditary liver diseases, functional cure of chronic hepatitis B, hepatitis C antiviral treatment, liver failure, fatty liver, etc. The department carries out liver disease health education from time to time to help patients correctly understand the disease, achieve self-management and improve the quality of life.
3) Multidrug-resistant bacteria and super-bacterial infections: Our department has long been committed to the monitoring of bacterial drug resistance and the research on the mechanism of drug resistance. We have undertaken a number of key and general projects of the National Fund. Team members have made great efforts to apply the basic research results to clinical treatment, and successfully treated a large number of patients with severe infections caused by multidrug-resistant bacteria and super-bacteria.
4) Diagnosis and treatment of rare pathogens: A large number of difficult rare pathogen infections were diagnosed by using pathogenic detection methods, including a new generation of gene sequencing detection methods.
Direction of Research
1. Pathogenic diagnosis of infectious diseases;
2. Drug resistance mechanism of pathogenic micro-organisms;
3. Epidemic control and treatment strategies of multi-drug resistant bacteria and super-bacteria;
4. Antiviral strategy and management of viral hepatitis
5. Diagnosis and treatment of complicated liver diseases.
Research Achievements
Our department has undertaken more than 50 national projects, including nearly 40 Natural Science Funds (including 2 key projects) and published more than 150 high-level articles as the first/corresponding author. In 2017, the research results on polymyxin (MCR) resistance were published in Lancet Infectious Diseases (IF 27.5), which was rated as one of the five "highly cited articles" in the field of infection in 2017. In 2018, research on drug resistance mechanisms and control strategies of multidrug resistant bacteria won the first prize of the science and technology progress award of the Zhejiang provincial government.